NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Systemic Light Chain Amyloidosis

Version 2.2014

NCCN.org
Systemic Light Chain Amyloidosis- Panel Members

* Kenneth C. Anderson, MD/Chair ‡
  Dana-Farber/Brigham and Women’s
  Cancer Center | Massachusetts General
  Hospital Cancer Center

* William Bensinger, MD/Vice-Chair † ⦁
  Fred Hutchinson Cancer Research Center/
  Seattle Cancer Care Alliance

Melissa Alsina, MD ‡
Moffitt Cancer Center

J. Sybil Biermann, MD ¶
University of Michigan
Comprehensive Cancer Center

Jason C. Chandler, MD †
St. Jude Children’s Research Hospital/
The University of Tennessee Health
Science Center

Caitlin Costello, MD † ‡ ⦁
UC San Diego Moores Cancer Center

Steven Devine, MD †
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Benjamin Djulbegovic, MD, PhD † ⦁ ⦁
Moffitt Cancer Center

Cristina Gasparetto, MD †
Duke Cancer Institute

Francisco Hernandez-ilizaliturri, MD †
Roswell Park Cancer Institute

Carol Ann Huff, MD †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Adetola Kassim, MD, MS ⦁ ⦁
Vanderbilt-Ingram Cancer Center

Amrita Y. Krishnan, MD ‡
City of Hope Comprehensive Cancer Center

Michaela Liedtke, MD ‡
Stanford Cancer Institute

Matthew Lunning, MD †
Fred & Pamela Buffet Cancer Center at The
Nebraska Medical Center

Ruby Meredith, MD, PhD ⦁
University of Alabama at Birmingham
Comprehensive Cancer Center

Noopur Raje, MD † ‡
Dana-Farber/Brigham and Women’s
Cancer Center | Massachusetts General
Hospital Cancer Center

Seema Singhal, MD ‡
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

George Somlo, MD † ‡ ⦁
City of Hope Comprehensive Cancer Center

*Keith Stockerl-Goldstein, MD † ⦁
Siteman Cancer Center at Barnes-Jewish Hospital
and Washington University School of Medicine

Steven P. Treon, MD, PhD †
Dana-Farber/Brigham and Women’s
Cancer Center | Massachusetts General
Hospital Cancer Center

Donna Weber, MD † ‡ ⦁
The University of Texas
MD Anderson Cancer Center

Joachim Yahalom, MD ⦁
Memorial Sloan-Kettering Cancer Center

† Medical oncology
‡ Hematology
⦁ Bone marrow transplantation
¶ Surgery/Surgical oncology
§ Radiotherapy/Radiation oncology
€ Pediatric oncology
⦁ Internal medicine
* Writing committee member

NCCN Staff
Rashmi Kumar, PhD
Dorothy A. Shead, MS

NCCN Guidelines Panel Disclosures

Version 2.2014, 10/04/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
NCCN Systemic Light Chain Amyloidosis Panel Members

Updates

Initial Diagnostic Workup (AMYL-1)

Clinical Findings and Primary Treatment (AMYL-2)

Primary Treatment References (AMYL-A)

Organ Involvement and Response to Treatment Based on Amyloidosis Consensus Criteria (AMYL-B)

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus
Updates in Version 2.2014 of the NCCN Guidelines for Systemic Light Chain Amyloidosis from Version 1.2014 include:

**MS-1**
- The addition of the discussion to reflect the changes in the algorithm.

Updates in Version 1.2014 of the NCCN Guidelines for Systemic Light Chain Amyloidosis from Version 1.2013 include:

**AMYL-2**
- Added the following regimens to the list of primary treatment options:
  - Lenalidomide/cyclophosphamide/dexamethasone
  - Pomalidomide/dexamethasone

**AMYL-A**
- Added a reference page for the primary treatment regimens listed on AMYL-2.

**AMYL-B**
- (page 2 of 2) Corrected very good partial response criteria from “dFLC <40 mg/dL” to “dFLC <40mg/L.”
INITIAL DIAGNOSTIC WORKUP

Clinical and amyloid-related assessment:
- Orthostatic vital signs
- History and physical

Laboratory evaluation (directed toward commonly affected organ systems):
- CBC with differential
- Prothrombin time (PT), Partial thromboplastin time (PTT), Factor X (if indicated)
- Hereditary amyloid testing (for African-American and peripheral neuropathy patients at minimum)
- Electrophoresis of serum and urine
- Immunoelectrophoresis of serum and urine
- Serum-free light chains
- 24-hour urinary protein and creatinine clearance
- Blood urea nitrogen, creatinine
- Brain natriuretic peptide (BNP) or NT-proBNP, troponin
- Alkaline phosphatase, liver enzymes, bilirubin

Pathologic evaluation:
- Bone marrow aspirate and biopsy with immunohistochemical staining for kappa and lambda and Congo red staining for amyloid
- Abdominal fat pad aspirate or involved organ biopsy as clinically indicated
- Mass spectrometry as clinically indicated

Special testing based on organ system involvement:
- Cardiac
  - EKG
  - Echocardiogram
  - Cardiac MRI (in certain circumstances)
  - Chest x-ray
- Liver and GI tract
  - Stool guaiacs
  - Gastric emptying scan (if gastroparesis present)
  - Ultrasound or CT scan to document craniocaudal liver span
- Peripheral nervous system
  - EMG (if clinically significant peripheral neuropathy)
  - Nerve conduction studies
- Other
  - Endocrine testing: TSH, cortisol
  - Pulmonary testing: Pulmonary function tests

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

It is essential to confirm that patients have primary systemic amyloidosis rather than hereditary amyloidosis, senile amyloidosis, or secondary amyloidosis. The amyloid deposits should be confirmed to be composed of light chains using immunohistochemistry or mass spectrometry. Immunohistochemistry for transthyretin or serum amyloid A component should be performed if kappa and lambda stains are negative.

Identification of light chains in the serum or urine without confirmation of the amyloid composition in tissue is not adequate as patients with other forms of amyloidosis may have an unrelated MGUS. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.
There are insufficient data to indicate the optimal treatment of amyloidosis, therefore, all patients should be treated in the context of a clinical trial when possible.

Options include:
- Bortezomib\textsuperscript{d} / cyclophosphamide / dexamethasone
- Bortezomib\textsuperscript{d} ± dexamethasone
- Bortezomib\textsuperscript{d} / melphalan / dexamethasone
- Cyclophosphamide / thalidomide / dexamethasone
- Dexamethasone / alpha-interferon
- High-dose melphalan\textsuperscript{e} with stem cell transplant
- Lenalidomide / cyclophosphamide / dexamethasone
- Lenalidomide / dexamethasone
- Oral melphalan / dexamethasone
- Pomalidomide / dexamethasone
- Thalidomide / dexamethasone
- Best supportive care

\textbf{See References for Primary Treatment Options (AMYL-A)}
REFERENCES FOR PRIMARY TREATMENT OPTIONS

There are insufficient data to indicate the optimal treatment of amyloidosis, therefore, all patients should be treated in the context of a clinical trial when possible.

- **Bortezomib/cyclophosphamide/dexamethasone**

- **Bortezomib ± dexamethasone**

- **Bortezomib/melphalan/dexamethasone**

- **Cyclophosphamide/thalidomide/dexamethasone**

- **Dexamethasone/alfa-interferon**
REFERENCES FOR PRIMARY TREATMENT OPTIONS

- **High-dose melphalan with stem cell transplant**

- **Lenalidomide/cyclophosphamide/dexamethasone**

- **Lenalidomide/dexamethasone**

- **Oral melphalan/dexamethasone**

- **Pomalidomide/dexamethasone**

- **Thalidomide/dexamethasone**

*Note: All recommendations are category 2A unless otherwise indicated.*

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### ORGAN INVOLVEMENT AND RESPONSE TO TREATMENT BASED ON AMYLOIDOSIS CONSENSUS CRITERIA (1 OF 2)

**Organ Involvement**

<table>
<thead>
<tr>
<th>Organ Involvement</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kidney</strong></td>
<td>24-hr urine protein &gt;0.5 g/day, predominantly albumin</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td>Echo: mean wall thickness &gt;12 mm, no other cardiac cause or an elevated NT-ProBNP (&gt;332 ng/L) in the absence of renal failure or atrial fibrillation</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td>Total liver span &gt;15 cm in the absence of heart failure or alkaline phosphatase &gt;1.5 times institutional upper limit of normal</td>
</tr>
<tr>
<td><strong>Nerve</strong></td>
<td>Peripheral: clinical; symmetric lower extremity sensorimotor peripheral neuropathy&lt;br&gt;Autonomic: gastric-emptying disorder, pseudo-obstruction, voiding dysfunction not related to direct organ infiltration</td>
</tr>
<tr>
<td><strong>Gastrointestinal tract</strong></td>
<td>Direct biopsy verification with symptoms</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td>Direct biopsy verification with symptoms&lt;br&gt;Interstitial radiographic pattern</td>
</tr>
<tr>
<td><strong>Soft tissue</strong></td>
<td>Tongue enlargement, clinical&lt;br&gt;Arthropathy&lt;br&gt;Claudication, presumed vascular amyloid&lt;br&gt;Skin&lt;br&gt;Myopathy by biopsy or pseudohypertrophy&lt;br&gt;Lymph node (may be localized)&lt;br&gt;Carpal tunnel syndrome</td>
</tr>
</tbody>
</table>

Revised Consensus Criteria for amyloidosis involvement from XII International Symposium on Amyloidosis:


**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## Hematologic and Organ Response Criteria

<table>
<thead>
<tr>
<th>Response</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematologic</strong></td>
<td></td>
</tr>
<tr>
<td>Complete Response</td>
<td>Negative serum and urine immunofixation, normal kappa/lambda free light chain ratio, normal bone marrow</td>
</tr>
<tr>
<td>Very Good Partial Response</td>
<td>dFLC &lt;40 mg/L</td>
</tr>
<tr>
<td>Partial Response</td>
<td>dFLC decrease ≥50%</td>
</tr>
<tr>
<td>No Response</td>
<td>Other</td>
</tr>
<tr>
<td><strong>Kidney</strong></td>
<td>50% decrease in 24-hour urinary protein excretion in the absence of worsening of creatinine clearance by ≥25% or increase in serum creatinine of ≥0.5 g/dL</td>
</tr>
<tr>
<td><strong>Cardiac</strong></td>
<td>Mean interventricular septal thickness decreased by 2 mm, 20% improvement in ejection fraction, improvement by 2 New York Heart Association classes without an increase in diuretic use, and no increase in wall thickness and/or a decrease in NT-ProBNP of ≥30% (minimum 300 ng/L) in patients with a creatinine clearance of ≥45 mL/min/1.73m²</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td>50% decrease in abnormal alkaline phosphatase value Decrease in liver size radiographically at least 2 cm</td>
</tr>
</tbody>
</table>

NCCN Guidelines Inde

Discussion

NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

**Overview** ............................................................................................................................... MS-2

Initial Diagnostic Workup ..................................................................................................... MS-2

Organ Involvement and Response to Treatment ........................................................................ MS-3

Primary Treatment ............................................................................................................. MS-3

**References** .................................................................................................................... MS-8
Overview

Primary systemic light chain amyloidosis is typically characterized by decreased numbers of monoclonal plasma cells in the bone marrow compared to multiple myeloma, however, the protein produced by these plasma cells has an affinity for visceral organs (such as kidney, heart, liver, and spleen), and this protein causes related end-organ dysfunction.\(^1\) Even though patients with this disease typically have a low burden of monoclonal plasma cells their survival is often poor due to the end organ damage by the amyloid protein. The therapy of systemic light chain amyloidosis is directed to recovering the function of the target organs by targeting the abnormal plasma cell clone.

Initial Diagnostic Workup

The initial diagnostic workup includes a history and physical (H & P) examination and evaluation of orthostatic vital signs. The following biological assessments are carried out: complete blood counts (CBC) with differential including platelet counts, blood urea nitrogen (BUN) content, serum creatinine, coagulation studies and electrolytes. Patients with systemic light chain amyloidosis are at risk for developing acquired factor X deficiency due to binding of factor X to amyloid fibrils.\(^2,3\) This deficiency typically responds to treatment of the underlying amyloidosis. Screening by serum electrophoresis alone may be inadequate, as it does not show a monoclonal spike in nearly 50% of cases. Therefore, all patients should undergo immunofixation electrophoresis of both serum and urine, which could detect a monoclonal (M) component. The work-up should also include quantification of proteinuria by 24 hour urine collection and measurement of creatinine clearance. The measurement of circulating serum free light chain (FLC) is a powerful diagnostic complement as the majority of patients with light chain amyloidosis will have abnormalities of the kappa or lambda chains or the kappa/lambda ratio. Additionally the FLC analysis is necessary to determine the hematologic response to therapy.\(^4,5\) Free light chains are cleared by the kidney therefore renal insufficiency increases the concentrations of FLC. In that case, the kappa/lambda ratio or the difference between involved and uninvolved free light chains should be monitored.\(^6\)

The diagnosis of amyloidosis requires the identification of amyloid deposits in tissues either by aspiration of abdominal subcutaneous fat and/or biopsy of the organs involved and the characterization of amyloidosis as a systemic light chain type requires the demonstration of the underlying plasma cell clone. Amyloid deposits are identified by bone marrow aspiration and biopsy followed by Congo red staining. Congo red staining of the subcutaneous fat aspirate is a reliable and noninvasive test reported to identify amyloid deposits in approximately 90% of patients.\(^7\) The monoclonal plasma cell population can be detected in bone marrow aspirates by immunohistochemical staining of kappa and lambda chains. Immunohistochemistry for transthyretin or the serum amyloid A component should be performed if kappa and lambda stains are negative. The stroma or blood vessels have been reported to be positive for amyloid in 60% of patients.\(^8\) Identification of light chains in the serum or urine without confirmation of the amyloid composition in tissue is not adequate as patients with other forms of amyloidosis may have an unrelated MGUS.\(^9\) Therefore it is essential to confirm that the amyloid deposits are composed of light chains by immunohistochemical methods, electron microscopy, or mass spectrometry.\(^10-12\) The NCCN panel members recommend mass spectrometry only if clinically indicated such as in cases where two potential amyloid precursor proteins are present including patients with monoclonal gammopathies who are African-American or elderly men, or who have dominant peripheral or autonomic neuropathy, family histories...
of amyloidosis, or coexisting inflammatory disorders. Since the
treatment is different in the various types of amyloidosis, it is essential
to confirm that patients have primary systemic amyloidosis rather than
hereditary amyloidosis, senile amyloidosis, or secondary amyloidosis.
Genetic testing especially for African-American and patients with
peripheral neuropathy must be done to identify the specific mutation in
the hereditary forms and avoid misdiagnosis.9,13

Specialized tests based on organ involvement
Majority of the patients present with one or more organs affected by
amyloidosis. The consensus criteria for organ involvement have been
recently updated at the 12th International Symposium on Amyloidosis.14

Cardiac involvement is diagnosed by imaging techniques such as
echocardiography (EKG), echocardiogram, chest x-ray, and
cardiovascular MRI in certain circumstances. Cardiovascular MRI has
been successfully used for the diagnosis and prognosis of amyloid
cardiomyopathy.15 Cardiac biomarkers in the serum provide a
quantitative assessment of cardiac dysfunction (troponin I or T) and
cardiac stress (brain natriuretic peptide (BNP) or NT-proBNP) are
important predictors of outcome in amyloidosis as well as part of the
cardiac response criteria.16,17

Liver and gastrointestinal (GI) involvement is diagnosed by elevated
serum alkaline phosphatase levels and bilirubin; performing stool guaiac
tests to detect fecal occult blood; gastric emptying scan if gastroparesis
is present; and ultrasound or CT scan to determine craniocaudal liver
span.

An electromyogram (EMG) or nerve conduction testing can be
performed if the patient has significant peripheral neuropathy to confirm
peripheral nervous system involvement.

Endocrine tests (thyroid stimulating hormone and cortisol levels) and
pulmonary function tests may be performed if involvement of the
endocrine system or lungs is suspected.

Organ Involvement and Response to Treatment
The first International consensus opinion for the definition of organ
involvement and response to treatment for systemic light chain
amyloidosis was published in 2005.18 These criteria has been recently
updated14,19 and the tables with definition for hematologic and organ
involvement and criteria for response to treatment are included in the
NCCN algorithms.

Primary Treatment
All current strategies include systemic therapy to destroy the plasma
cells responsible for the synthesis of immunoglobulin light chain.
Several active regimens are now available for the treatment of systemic
light chain amyloidosis. Most are those derived from the treatment of
multiple myeloma. The goals of therapy include eliminating the
misfolded amyloid light chains as promptly as possible, minimizing
treatment toxicity, and supporting the function of the damaged organs.
The consensus criteria for hematologic and organ response have been
recently updated at the 12th International Symposium on Amyloidosis.14

High-dose melphalan followed by stem cell transplant
High-dose melphalan followed by stem cell transplant (SCT) is one of
the therapeutic options listed by the NCCN panel. However, patients
have to be carefully selected as this treatment modality is associated
with significant treatment-related mortality.20-25 The extent of organ
involvement is considered as predictor of outcome.23,26,27

In eligible patients, high-dose chemotherapy along with stem cell
support has been associated with higher response rates and improved
overall survival (OS) than standard chemotherapy. The best outcomes following SCT have been reported in patients who achieve complete response (CR) to high-dose primary chemotherapy including improvement of organ-related disease. The most significant leading indicator of the durability of treatment benefits is the depth of the response to therapy measured by the lowest post-transplantation serum free light chain level.

There are a number of groups that have evaluated dose-adjustment of the high dose melphalan during a transplant based on factors such as age, number of organs involved and presence or absence of cardiac involvement. The reported toxicity of reduced-dose of melphalan is substantially less than high dose. However it should be noted that higher doses of melphalan are associated with a higher CR rate, and improved OS and event-free survival (EFS). Long-term follow-up study of the 74 patients who underwent SCT found that 32 (43%) survived greater than 10 years. The baseline characteristics identified in the study as statistically and significantly different between those who survived long term versus those who did not are 1) the number of organs involved; 2) interventricular septal thickness; 3) total cholesterol; and 4) urine total protein.

Melphalan/Dexamethasone
Melphalan and dexamethasone regimen has also been used in the management of systemic light chain amyloidosis. It has shown promising results in patients with primary amyloidosis who are ineligible for SCT. A small study reported hematologic response in 67% (n = 31) and complete remission in 33% (n = 15) treated with melphalan and high-dose dexamethasone in a median of 4.5 months. Improvement in organ function was seen in 48% (n = 22). The updated results reported that the CR induced by melphalan and high-dose dexamethasone was maintained in 70% of the patients for up to 3 years, and survival at a median follow-up of 5 years was about 50%.

The French Myeloma Collaborative Group compared melphalan and dexamethasone to high-dose melphalan followed by SCT in a randomized trial and found no significant differences for hematologic or organ responses. In a recent update, with a longer follow-up, the authors found that survival or remission duration were not statistically different between melphalan and dexamethasone versus high-dose melphalan followed by SCT even after eliminating treatment related mortality in from SCT arm.

Dexamethasone/Alpha-interferon
In a multicenter, cooperative group trial (n = 93), patients were treated with induction therapy with dexamethasone, followed by maintenance therapy with dexamethasone and alpha interferon. Complete hematologic response was seen in 24% and improvement of organ dysfunction in 45% of the evaluable patients; overall median survival was 31 months; and 2-year survival rate was 60%.

Thalidomide/Dexamethasone
Thalidomide in combination with dexamethasone was studied in a small group of patients. Only 11 patients out of the 31 enrolled tolerated 400 mg/day of thalidomide for a median of 5.7 months; 20 patients experienced toxicity of grade 3 or more. This combination although active is associated with substantial toxicity.

Cyclophosphamide/Thalidomide/Dexamethasone
Thalidomide has also been combined with cyclophosphamide, and dexamethasone. Wechalekar et al studied the use of oral regimen of cyclophosphamide, thalidomide, and dexamethasone (CTD) in phase II study involving 75 patients with advanced systemic light chain...
amyloidosis, including 44 patients with clonal relapse after prior therapy. Elderly patients (> 70 years), those with heart failures, and those with significant fluid overload received a risk attenuated CTD regimen (CTDa). The study reported overall hematologic response in 74% (48 out of 65 evaluable patients treated with either CTD or CTDa), including complete responses in 21% (n = 14) and partial responses in 53% (n = 34). About 8% (n = 6) discontinued treatment due to toxicities within 8 weeks of initiating therapy. Grade 2 toxicities were reported in 52% (n = 39) of patients and treatment related mortality was 4% (n = 3). Among patients with complete and partial hematologic response, the three year estimated OS based on the data was 100% and 82% respectively.

**Lenalidomide/Dexamethasone**
 Lenalidomide is an analogue of thalidomide. Phase II studies have shown lenalidomide in combination with dexamethasone is active in the treatment of patients with systemic light chain amyloidosis, including those with relapsed/refractory disease. Common adverse effects reported in patients on the study included rash, cytopenia, and fatigue. The incidence of dermatologic adverse effects with combination of lenalidomide and dexamethasone was found to be higher in patients with amyloidosis compared to those with myeloma. In addition, progressive azotemia and serious cardiac and renal toxicity has been reported in patients with amyloidosis, warranting careful monitoring of patients on this regimen.

**Lenalidomide/cyclophosphamide/dexamethasone**
 In phase II study, 35 patients of who 24 were newly diagnosed with systemic amyloidosis, were treated with the combination of lenalidomide, cyclophosphamide, and dexamethasone.

About 63% of patients had cardiac involvement; 3% had stage III disease and 28% had ≥ 3 organs involved. The overall hematologic response rate to lenalidomide, cyclophosphamide and dexamethasone was 60%, including 40% with very-good partial response or better. Assessment of response using serum FLC assay, revealed 77% of patients had a hematologic response and 29% of these patients showed organ responses. The median hematologic progression-free survival reported in this trial was 28.3 months and the median overall survival was 37.8 months. Hematologic toxicity was the predominant adverse event reported in this study.

**Pomalidomide/dexamethasone**
 Pomalidomide, like lenalidomide is an analogue of thalidomide. The safety and efficacy of pomalidomide and dexamethasone was studied in a prospective phase II study. Patients with previously treated systemic light chain amyloidosis (n = 33) were enrolled in the trial and upon treatment with pomalidomide and dexamethasone, confirmed response was reported in 48% (n = 16) with a median time to response of 1.9 months. The median overall was 28 months and progression-free survival rates was 14 months; the overall and progression-free survival rate at one year were 76% and 59%, respectively.

**Bortezomib**
 Bortezomib is rapidly active in systemic light chain amyloidosis with high rates of hematologic and organ responses. Clinical studies have reported bortezomib with or without dexamethasone to be active in untreated and relapsed amyloidosis. The National Amyloidosis Center in Britain reported on 20 relapsed or refractory patients treated with bortezomib. A hematologic response was seen in 80% (n = 16) of patients, 15% (n = 3) achieved CR and 65 % (n =13) achieved a partial response. In a multicenter phase I/II dose-escalation study of
bortezomib, hematologic responses were seen in 15% (15 out of 30 evaluable pretreated patients) with CR rate of 20% (n = 6). Bortezomib was well tolerated at doses up to 1.6 mg/m² on a once-weekly schedule and 1.3 mg/m² on a twice-weekly schedule. The median time to response was 1.2 months. Although once-weekly and twice-weekly bortezomib was seen to be generally well tolerated in the study, the once-weekly bortezomib regimen was associated with lower neurotoxicity.

**Bortezomib/Dexamethasone**

Efficacy of bortezomib in association with dexamethasone was also evaluated in small study of 18 patients included those who had relapsed or progressed on prior therapies. Out of 16 evaluable patients, hematologic response was seen in 94% (n = 14) including complete response in 44% (n = 7). A phase II clinical trial studied the bortezomib and dexamethasone adjuvant therapy in 21 patients not achieving a CR post-SCT. At 1 year post-SCT out of 12 evaluable patients, there was an overall response rate of 92% (n= 11), 67% (n = 8) achieved a CR and 50% (n = 6) had organ responses. Data from three international centers from 94 patients (18 previously untreated) treated with bortezomib reported a 71% (67 out of 93 patients) overall response rate with CR in 25% (47% CR was in previously untreated patients).

**Bortezomib/Melphalan/Dexamethasone**

Combining weekly bortezomib with melphalan in small series of patients yielded hematologic response rates of 94%. Bortezomib in combination with melphalan and dexamethasone was evaluated in a small phase II trial and results with a best-response rate of over 80% and a CR rate of 42%. These encouraging preliminary results and the fact that bortezomib in combination oral melphalan and prednisone has improved survival in patients with myeloma had led to an ongoing phase III trial is comparing bortezomib in combination with melphalan and dexamethasone to melphalan and dexamethasone as frontline therapy in patients with systemic amyloidosis.

A collaborative study at three large European amyloid centers analyzed the outcomes of 428 patients treated with oral CTD; oral melphalan/dexamethasone; bortezomib/dexamethasone with or without an alkylator; cyclophosphamide/lenalidomide/dexamethasone; or autologous SCT as first line treatment for systemic light chain amyloidosis. The organ and NT-proBNP responses were found highest in the group treated with bortezomib/dexamethasone (53% and 32%), followed by CTD (38% and 12%), autologous SCT (30%), melphalan/dexamethasone (23% and 19%) and cyclophosphamide/lenalidomide/dexamethasone (12% and 0%).

**Cyclophosphamide/Bortezomib/Dexamethasone**

Recently, the combination of cyclophosphamide, bortezomib and dexamethasone (CyBORD) is reported with high hematologic response rates and CR in two independent studies. Mikhaiel et al reported analysis of 17 patients, 10 had no previous therapy. The patients were treated with weekly administration CyBORD before autologous transplantation, as an alternate to transplantation for transplant ineligible patients, or as salvage therapy for patients with relapsed disease. The hematological responses were seen in 94% and CR rate was 71%. The median duration of response was 22 months. Organ response was observed in 50% of the patients with renal involvement. Three patients originally ineligible for autologous SCT, became eligible after treatment with CyBORD.

In the study by Venner et al, 43 patients were treated with biweekly administration of CyBORD, Twenty out of the 43 patients were treatment naïve. The hematologic response rate was 81.4% with a CR
rate of 39.5%. Due to the biweekly administration, peripheral neuropathy was seen in 30% of the patients.62,63 A small retrospective study of patients newly diagnosed with systemic amyloidosis and multiple myeloma treated with the CyBorD regimen containing subcutaneous bortezomib reported a high response rate and minimal toxicity.64 These results need to be validated in prospective trials.

NCCN Recommendations for Primary Treatment
The NCCN panel members recommend that treatment of systemic light chain amyloidosis should be in the context of a clinical trial when possible because data are insufficient to identify optimal treatment of the underlying plasma cell disorder.

Based on the evidence discussed above, the current NCCN Guidelines list the following as therapeutic considerations for management of patients with systemic light chain amyloidosis (all category 2A recommendation) along with best supportive care: high-dose melphalan followed by autologous SCT; oral melphalan and dexamethasone; dexamethasone in combination with alpha-interferon; thalidomide plus dexamethasone; lenalidomide and dexamethasone; Lenalidomide/cyclophosphamide/dexamethasone; pomalidomide and dexamethasone; bortezomib with or without dexamethasone; bortezomib with melphalan plus dexamethasone; cyclophosphamide, thalidomide, and dexamethasone; and cyclophosphamide, bortezomib, and dexamethasone.

The treatment options are listed alphabetically in the NCCN Guidelines and do not indicate or imply preference. As the optimal therapy for systemic light chain amyloidosis still remains unknown, the NCCN Panel Members strongly encourage treatment in the context of a clinical trial when possible.
References


58. Landau H, Hoffman J, Hassoun H, et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell...
http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8540.

http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8024.


http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/988.


63. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387-4390. Available at: 

64. Shah GL, Kaul E, Fallo S, et al. Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity. ASH Annual Meeting Abstracts 2012;120:2968-. Available at: 
http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/2 1/2968.